Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S314700, C548S322500, C548S323500, C548S324500, C548S325100, C548S331500, C548S332100, C546S210000, C514S397000, C514S398000, C514S400000
Reexamination Certificate
active
10757625
ABSTRACT:
The invention relates to novel 2-Oxy, 2-Amino, and 2-Thio-imidazole compounds of formula (I):wherein all variables are as herein defined, pharmaceutical compositions containing the compounds and methods of using them in the treatment of neurological disorders and other disorders and conditions mediated by the histamine H3receptor.
REFERENCES:
patent: 3714179 (1973-01-01), Tweit
patent: 3886160 (1975-05-01), Tweit
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5217986 (1993-06-01), Pomponi et al.
patent: 5352707 (1994-10-01), Pompni et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 2005/0250948 (2005-11-01), Jones et al.
patent: 0 978 512 (2000-02-01), None
patent: 02306237 (1990-12-01), None
patent: WO99/42458 (1999-08-01), None
Jordaan, A.; Arndt, R. R., Journal of Heterocyclic Chemistry, 5(5), 723-5 (English) 1968.
Garcia Gonzalez, F.; Fernandez Bolanos, J.; Fuentes Mota, J., Carbohydrate Research, 22(2), 436-40 (English) 1972.
Renato M.E. Sabbatini,. Re: The Cyclotron and PET. In Brain & Mind an electronic magazine about Neuroscience [online], Mar. 1997 [retrived Jul. 15, 2003]. Retrived from the internet <http://www.epub.org.br/cm
01/pet/petcyclo.htm>.
Phillips, J.G. et al, Ann. Reports Med. Chem., 31, 1998, pp. 31-40.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Phillips, Brian T.; Claremon, David A.; Varga, Sandor L., Synthesis (9), 761-3 (English) 1990.
Anjaneyulu, B. et al. Synthesis of 14C-Labelled 1-Methanesulphonyl-3-(1-methyl-5-nitro-1H-imidazol-2-yl)-2-imidazolidinone, (Go 10213). J. Labelled Compd. Radiopharm. (1983) 20(8):951-961.
Iemura, R. et al. Synthesis of Benzimidazole Derivatives as Potential. H1-Antihistaminic Agents. J. Heterocycl. Chem. (1987) 24:31-37.
Iwata, R. et al. Synthesis of 3-[1H-Imidazol-4-yl]propyl 4-[18F]fluorobenzyl Ether ([18 F]Fluoroproxyfan): A Potential Radioligand for Imaging Histamine H3 Receptors. J. Labelled Compd. Radiopharm. (2000) 43:873-882.
Jarosinski, M.A.; Anderson, W.K. Preparation of Noncondensed 2-Substituted 1-Methylimidazoles via Ipso Substitution Reaction on 2-Sulfinyl or 2-Sulfonyl Derivatives of 4,5-Disubstituted 1-Methylimidazoles. J. Org. Chem. (1991) 56(12):4058-4062.
Ohta, S. et al. Synthesis and Application of Imidazole Derivatives. Introduction of Carbogenic Substituents into the 5-Position of 1-Methyl-1H-imidazole. Chem. Pharm. Bull. (1992) 40(10):2681-2685.
Phillips, B.T. et al. Preparation of 5-Substituted 2-Mercapto-1-methylimidazoles. Direct Metalation of 2-Mercapto-1-methylimidazole. Synthesis (1990) :761-763.
Schnettler, R.A. et al. 4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a New Class of Cardiotonic Agents. J. Med. Chem. (1982) 25:1477-1481.
Shapiro, G.; Marzi, M. Synthesis of 2,5-Dilithio-1-methylimidazole. Tetrahedron Lett. (1993) 34(21):3401-3404.
Leurs, R. et al; “Therapeutic potential of histamine H3 recepto agnoists and antagonitsts” Trends n Pharmacological sciences, Elsevier Trends Journal, Cambridge, BG, vol. 19, No. 5, May 1, 1998; pp. 177-184, XP004121095.
Tozer, M.J., et al.; “From Histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3 receptor antagonists”; Bioorganic & Medicinal CHemistry Letters, OXFORD, GB, vol. 9, No. 13, Jul. 5, 1999, pp. 1825-1830. XP004168846.
Gonzalez, F. Garcia et al.: “Synthesis of 3-aryl(alkyl)-4-(D-arabino-tetrahydroxybutyl)imidazolin—2-thiones”; J. Carbohydrate Research. 22(1972), 436-40.
Jordaan, A. et al.: “The Synthesis of 1-Methyl-5-(α-indolyl)imidzaole”; J. of Heterocyclic Chemistry, 5(5), 723-5 (1968).
Phillips, J.G. et al.: Chapter 4. Recent Advance in Histamine H3Receptor Agents. Annual Reports in Medicinal Chem., 33, 1998, pp. 31-40.
Sabbatini, Renato M.E.: Re: The Cyclotron and PET. In Brain & Mind an electronic magazine about Neuroscience [online]. Mar. 1997. Retrieved from the Internet <http://www.epub.org.br/cm
01/pet/petcyclo.htm>.
Arrang, J.M. et al.; “Auto-inhibiton of brain histamine release mediated by novel class (h3) of histamine receptor” Nature; Apr. 1983; 302:832-837.
Ash, A.S.F. et al; “Receptors Mediating Some Actions of Histamine”; Br. J. Pharmac. Chemother.; 1966 27:427-439.
Barnes, J.C. et al; “The selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in vivo”; Soc. Neurosci. Abstr.; 1993 19:1813.
Bioworld Today, Mar. 2, 1999, p. 3.
Black, J.W. et al.; “Definition and Antagonism of Histamine H2-receptors”; Nature; Apr. 1972; 236:385-390.
Ding, Y. S. et al. “Synthesis of High Specific Activity (+)-and (−)6-[18F]Fluoronorepinephrine via the Nucleophilic Aromatic Substitution Reaction”. J. Med. Chem. (1991) 34:767-771.
Ganellin, C.R. et al.; “Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists”; Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.); 1998 331:395-404.
Garbag, M. et al; “S-[2-(4-Imidazolyl)ethyl]Isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist”; J. Pharmacol. Exp. Ther.; 1992; 263(1):304-310.
Gilatech, Inc.; “Gilatech's first drug candidate begins phase I human clinical trials”; Gilatech Inc. Press Release; Nov. 5, 1998.
Ichinose, M. et al; “Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo”; P.J. Eur. J. Pharmacol; 1989; 174:49-55.
Imamura, M. et al.; “Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release 1,2”; J. Pharmacol, Exp. Ther.; 1994 271(3):1259-1266.
Jones, R.G. Studies on Imidazoles. II. The Synthesis of 5-Imidazolecarboylates from Glycine and Substituted Glycine Esters. J Am. Chem Soc. (1949) 71:644-647.
Korte, A. et al; “Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by Na-Methylhistamine”; Biochem. Biophys. Res. Commun.; May 1990; 168(3):979-986.
Krause, M. et al.; “The Histamine H3 Receptor-A Target for New Drugs”; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998; 175-196.
Leurs, R. et al; “The medicinal chemistry and therapeutic potentials of ligands of the histamine h3 receptor” Prog. Drug. Res.; 1995; 45:107-165.
Lin, Jian-Sheng et al. “Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat”; Brain Res.; 1990; 523:325-330.
Linney, I.D. et al; “Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists”; J. Med. Chem.; 2000; 43:2362-2370.
Lovenberg, T.W. et al; “Cloning and Functional Expression of the Human Histamine H3 Receptor”; Mol. Pharmacol; 1999 55:1101-1107.
Lovenberg, T.W. et al. Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. (2000) 293:771-778.
Machidori, H. et al; “Zucker obese rats:defect in brain histamine control of feeding”; Brain Res.; 1992; 590:180-186.
Mcleod, R.L. et al; “Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist”; Soc. Neurosci. Abstr.; 1996; 22:2010.
Monti, J.M. et al; “Effects of selective activation or blockade of the histamine h3 receptor on sleep and wakefulness”; Eur. J. Pharmarcol.; 1991; 205:283-287.
Morisset, S. et al; “High constitutive activity of native H3 receptors regulates histamine neurons in brain”; Nature; Dec. 2000; 408:860-864.
Oda, Tamaki et al.; “Molecular Cloning and characterization of a Novel Type of Histamine Receptor Preferentially Expressed In Leukocytes”; J. Biol. Chem.; Nov. 2000; 275(47):36781-36786.
Panula, P. et al.; “Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease”Soc. Neurosci. Abstr.; 1995; 21:1977.
P
Bogenstaetter Michael
Carruthers Nicholas I.
Jablonowski Jill A.
Lovenberg Timothy W.
Ly Kiev S.
Habte Kahsay
Ortho-McNeil Pharmaceutical , Inc.
LandOfFree
2-oxy, 2-amino, and 2-thio-imidazole compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-oxy, 2-amino, and 2-thio-imidazole compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-oxy, 2-amino, and 2-thio-imidazole compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747714